Nascent Biotech Inc. financial data

Symbol
NBIO on OTC
Industry
Pharmaceutical Preparations
Location
631 Us Hwy 1, Suite 407, North Palm Beach, FL
State of incorporation
Nevada
Fiscal year end
March 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 76.7 % +160%
Debt-to-equity -430 % -200%
Return On Equity 1.03K % +526%
Return On Assets -313 % +19.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 172M shares +21.8%
Common Stock, Shares, Outstanding 172M shares +19.9%
Entity Public Float 19.2M USD 0%
Common Stock, Value, Issued 172K USD +19.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 100K USD -58.2%
General and Administrative Expense 422K USD +10.1%
Operating Income (Loss) -2.09M USD -2.22%
Net Income (Loss) Attributable to Parent -1.92M USD +5.71%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 227K USD +188%
Assets 227K USD +188%
Liabilities, Current 742K USD -39.9%
Liabilities 742K USD -39.9%
Retained Earnings (Accumulated Deficit) -24.6M USD -11.2%
Stockholders' Equity Attributable to Parent -515K USD +53.9%
Liabilities and Equity 227K USD +188%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -325K USD -99.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 172M shares +19.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 47.4K USD +400%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 1.24M USD -29.5%
Deferred Tax Assets, Operating Loss Carryforwards 1.24M USD -29.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Additional Paid in Capital 24M USD +14.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 149K USD -91.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%